Originated in the year of 1582 A.D., Mayinglong is among the first batch of China’s time-honored brands accredited by Ministry of Commerce. Ever since its foundation, it has been devoting to the professional development of pharmaceutical industry and focusing on the core orientation of proctologic hemorrhoids treatment. After consecutive years of fast and healthy development, Mayinglong, now listed in Shanghai Stock Exchange, has grown to be a professional, multifunctional and international company dedicated in pharmaceutical manufacturing, pharmaceutical research and development, medicine retail and wholesale and chain hospitals.

With complete production capacities, Mayinglong now manufactures more than 30 different dosage forms and 20 exclusive types of pharmaceuticals, including Mayinglong Musk Hemorrhoids Ointment, Mayinglong Musk Hemorrhoids Suppository and Long Zhu Ointment. Besides, more than 300 varieties of pharmaceuticals are authorized NMPN (national medicine permission number). Mayinglong has the capacity of producing approximately a hundred million of tubes of diversified ointment and pellets of suppositories. In addition, it possesses first-level production facilities and the assembly lines and accessories for producing major varieties is technologically leading in the nationwide.
The company now has 23 technical personnel, 10 of whom are qualified with intermediate or senior professional titles and besides, a group of subject leaders are engaged in the research of medication synthesis, extract of TCM, pharmaceutical manufacturing engineering, pharmacology and toxicology and clinical experimental assessment. Mayinglong is assessed “Provincial Hi-Tech Enterprise” and its R&D center awarded “Enterprise Technology Center” by Hubei provincial government and Wuhan municipality government. 

Through the years, Mayinglong has not only established long-term strategic cooperation with School of Pharmaceutical Science of Peking University, China Pharmaceutical University and other research institutions, but also jointly set up a post-doctoral workstation with Peking University sanctioned by State Ministry of Personnel, further enhancing the steady improvement of technology strength and conforming capabilities in pharmaceutical research and development. Encompassing the core orientation, Mayinglong extensively carries out the research and development in serialization products. Currently, 5 types of hemorrhoids pharmaceuticals are being sold and 7 items on hemorrhoids treatment are under research, which covers ointment, suppository, oral troche and lotion of TCM and oral troche of western medicine. Besides, it has already established one item on developing 6 types of proctologic hemorrhoids pharmaceuticals, together with other 16 various items under research.
With a relatively complete marketing management system and a marketing network platform that covers the whole country, Mayinglong has established long-term cooperation with more than 300 high-ranking enterprises in medicine circulation, promoting its products sold far-forth in Southeastern Asia, Europe and America. It is calculated that the annual sales of hemorrhoids treatment pharmaceuticals amounts to a hundred of million yuan. Statistics provided by South Medical Economy Institution of SFDA show that Mayinglong has covered 40% of the wholesale market of hemorrhoids pharmaceuticals, being the first brand in hemorrhoids treatment.
Mayinglong and its subsidiary companies have respectively certificated GMP and GSP quality management criterion system accredited by SFDA, Environment Management System ISO14000 and Occupation Safety and Health Management System OHSAS18000 awarded by SGS, an authoritative notified body, being the first in pharmaceutical industry that has past the whole three authentications. Mayinglong ranks 214th on the chart of “China’s Most Valuable Brands 2008”, co-estimated by the World Brand Lab and World Executive Institute, with its brand value amounting to 3.508 billion yuan. In late 2005, Mayinglong was awarded “China’s Most Influential Hemorrhoids Medication”, co-evaluated by China Daily, China Enterprise Culture Improvement Association, China Quality and Brand Magazine and other three public media. On June 1, 2006, Mayinglong was awarded “The Chinese Famous Trademark” by State Administration of Industry and Commerce, being the first and the sole one in hemorrhoids treatment.
On May 17, 2004 Mayinglong was listed in Shanghai Stock Exchange, which symbolized that Mayinglong has become a public-traded company and hence acquired a channel of sustainable financing and a platform of normative operation. Mayinglong ranks 18th on “China’s Most Respected Listed Companies”, a chart of “Best Corporate Governance for China’s Listed Companies in the Year 2005”, co-estimated by World Finance Lab, The Wall Street Wire and World Executive Weekly. In 2007, due to its complete management structure and outstanding achievement, Mayinglong was selected sampling stock in “Management Index of China’s Listed Companies” compiled by Shanghai Stock Exchange. Besides, in 2005 Mayinglong ranks 39th among China’s most competitive listed companies, coming out on top of all the listed pharmaceutical companies.
With a historical culture that has been passed down for more than 400 years, Mayinglong has gradually cultivated an enterprise culture system with its own characteristics. Upholding the operation tenet of “creating health for customers, creating wealth for shareholders, creating opportunities for employees, creating efficiency for society”, Mayinglong not only advocates the philosophy of “cultivating mentality in honesty and fostering behavior in diligence”, but also proposes the management concept of “steady management, coordinated development” and the value of “resource increment”, carrying forward the culture spirit of “being vigorous and exuberant”. Regarding the modernization of traditional Chinese medicine as its own task, Mayinglong will carry forward the cause and forge ahead into the future and advance with times under the guidance of brand management strategy.